KRYS
Krystal Biotech, Inc. · Healthcare · Biotechnology
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1.33K | $436,744 | n/a | −1 |
| Q2 2026 | 107 | +2 | 18.97M | $7.05B | +12 | −11 |
| Q1 2026 | 109 | 0 | 17.81M | $4.60B | +7 | −8 |
| Q4 2025 | 109 | +2 | 19.84M | $4.89B | +3 | n/a |
| Q3 2025 | 18 | +1 | 16.09M | $2.84B | +2 | −2 |
| Q2 2025 | 15 | -1 | 14.75M | $2.03B | n/a | −1 |
| Q1 2025 | 13 | +1 | 3.64M | $657.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 3.56M | $557.49M | +1 | n/a |
| Q3 2024 | 10 | +2 | 2.25M | $408.78M | +2 | n/a |
| Q2 2024 | 8 | n/a | 2.10M | $386.05M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 878.16K | n/a | $161.26M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 600.14K | n/a | $110.21M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (被动) | 580.22K | n/a | $106.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (被动) | 11.34K | n/a | $2.08M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 11.05K | n/a | $2.03M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 11.02K | n/a | $2.02M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | AQR Capital Management ✦ | 7.59K | n/a | $1.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 2.57K | n/a | $471,955 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 364 持有人, 28.19M 股份, $7.07B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director, 10% owner · 399 股 · $146,256
Officer, Director, 10% owner · 3.96K 股 · $1.42M
Officer, Director, 10% owner · 3.18K 股 · $1.14M
Officer, Director, 10% owner · 3.39K 股 · $1.22M
Officer, Director, 10% owner · 2.32K 股 · $836,281
Officer, Director, 10% owner · 1.24K 股 · $449,120
Officer, Director, 10% owner · 1.99K 股 · $722,404
Officer, Director, 10% owner · 565 股 · $205,287
Officer, Director, 10% owner · 1.33K 股 · $484,390
Officer, Director, 10% owner · 826 股 · $301,832
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论